Apogee Therapeutics, INC 8-K filings

Apogee Therapeutics has begun dosing healthy volunteers in a Phase 1 clinical trial for APG808, a novel antibody targeting IL-4R for the treatment of COPD and other inflammatory diseases.

Apogee Therapeutics has released positive interim Phase 1 data for its drug candidate APG777, showing a favorable safety profile and extended half-life, leading to accelerated Phase 2 trial plans.

Apogee Therapeutics reports positive interim Phase 1 results for APG777, showing a 75-day half-life and plans for a Phase 2 trial, along with full year 2023 financial results.